A multicenter, cohort study assessing the potential impact of treatment with inotuzumab ozogamicin on chimeric antigen receptor t-cell therapy in children with relapsed or refractory acute lymphoblastic leukemia
Latest Information Update: 14 Feb 2023
At a glance
- Drugs CAR-T cell therapies (Primary) ; Inotuzumab ozogamicin (Primary) ; Blinatumomab
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 01 Jan 2023 Results investigated whether prior use of inotuzumab ozogamicin (InO),may impact CAR T-cell manufacturing or efficacy via pre-CART-19 depletion of the B-cell compartment published in the Leukemia
- 27 Jan 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition